Fig. 4

Distribution of MET TKD mutations. a–c Distribution of MET TKD mutations in baseline patients (a) and patients who acquired MET mutations post-EGFR-TKI (b) and post-MET-TKI (c) treatment. d The bar graph demonstrates the proportions of patients in three cohorts harboring each type of MET TKD mutation. e Schematic demonstration of potential mechanisms of acquiring MET TKD mutations after EGFR-TKI treatment